PMID: 9544705Apr 17, 1998Paper

Double-cleavage production of the CTL epitope by proteasomes and PA28: role of the flanking region

Genes to Cells : Devoted to Molecular & Cellular Mechanisms
N ShimbaraK Tanaka

Abstract

Proteasomes are known to produce major histocompatibility complex (MHC) class I ligands from endogenous antigens, and the gamma-interferon-inducible proteasome activator PA28 has been thought to play an important role in the generation of immunodominant MHC ligands by proteasomes. Several attempts have been made to show that proteasomes have the ability to yield cytotoxic T lymphocyte (CTL) epitopes effectively from model polypeptides derived from viral and intracellular proteins in vitro, but their antigen processing mechanism is poorly understood. Proteasomes produce the tumour rejection antigen precursor peptide pRL1b (SIIPGLPLSL), but not pRL1a (IPGLPLSL), bound to the H-2Ld molecule, from synthetic peptides covering the CTL epitope. This double cleavage production of pRL1b by proteasomes seemed to depend on the length of the flanking regions adjacent to either end of the CTL epitope, in which their successive deletions caused the almost complete prevention of pRL1b excision. The newly identified PA28 collaborates with proteasomes for efficient production of pRL1b, by promoting not only single cleavage of all susceptible peptides, but also dual cleavage in some peptides harboring certain characteristic lengths. The flanking...Continue Reading

Citations

Jun 11, 2002·Journal of Molecular Biology·Björn PetersHermann-Georg Holzhütter
Feb 27, 1999·Current Opinion in Immunology·K Früh, Y Yang
Dec 22, 1999·The Biochemical Journal·M RechsteinerV Ustrell
Sep 30, 2000·European Journal of Biochemistry·R StohwasserH G Holzhütter
Nov 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Amy M Ruschak, Lewis E Kay
Oct 5, 2011·Molecular & Cellular Proteomics : MCP·Noel García-MedelJosé A López de Castro
Oct 3, 2009·Journal of Biomolecular Structure & Dynamics·Seema Mishra, Subhata Sinha
Jul 18, 2002·The Journal of Experimental Medicine·Taketoshi YamanoHeiichiro Udono
May 29, 2002·The EMBO Journal·Paolo CascioAlfred L Goldberg
Jan 13, 2000·Immunological Reviews·I A YorkK L Rock
May 7, 2008·Biochemistry. Biokhimii︠a︡·V I MelnikovaL A Zakharova
Jun 8, 1999·Annual Review of Immunology·K L Rock, A L Goldberg
Jun 28, 2014·Biomolecules·Paolo Cascio
Oct 5, 2010·Cellular Immunology·Victoria I MelnikovaLiudmila A Zakharova
Sep 7, 2013·Journal of Zhejiang University. Science. B·Yu-feng LuZhi-yang Li
Dec 2, 2004·Biochimica Et Biophysica Acta·Peter-M Kloetzel
Feb 5, 2013·Biochemical and Biophysical Research Communications·Masaaki SugiyamaKoichi Kato
Nov 3, 1998·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·K Tanaka, T Chiba
Oct 21, 2017·Cancer Metastasis Reviews·James J Driscoll, Magen Brailey
Jul 4, 2006·Ontogenez·N P Sharova
Mar 27, 2001·Nature Reviews. Molecular Cell Biology·P M Kloetzel
Apr 22, 2015·Bioorganicheskaia khimiia·A Sh OrlovaN P Sharova
Jan 7, 2015·Molecular Systems Biology·Bertrand FabreMarie-Pierre Bousquet-Dubouch
Aug 29, 1998·The Journal of Biological Chemistry·N ShimbaraK Tanaka
Jul 22, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Taketoshi YamanoHeiichiro Udono
Jul 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·C KnuehlP M Kloetzel
Mar 9, 2004·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lance F BartonJohn J Monaco
May 9, 2000·The Journal of Biological Chemistry·N TanahashiK Tanaka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.